Evaluation of an Individualized Dose Titration Regimen of Patiromer to Prevent Hyperkalaemia in Patients with Heart Failure and Chronic Kidney Disease
Open Access
- 25 January 2018
- journal article
- research article
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 5 (3) , 257-266
Abstract
Hyperkalaemia risk precludes optimal renin–angiotensin–aldosterone system inhibitor use in patients with heart failure (HF), particularly those with chronic kidney disease (CKD). Patiromer is a sodium-free, non-absorbed potassium (K+)-binding polymer approved for the treatment of hyperkalaemia. In PEARL-HF, patiromer 25.2 g (fixed dose) prevented hyperkalaemia in HF patients with or without CKD initiating spironolactone. The current study evaluated the effectiveness of a lower starting dose of patiromer (16.4 g/day) followed by individualized titration in preventing hyperkalaemia and hypokalaemia when initiating spironolactone. This open-label 8-week study enrolled 63 patients with CKD, serum K+ 4.3–5.1 mEq/L, and chronic HF, who, based on investigator opinion, should receive spironolactone. Eligible patients started spironolactone 25 mg/day and patiromer 16.8 g/day (divided into two doses), with patiromer titrated to maintain serum K+ 4.0–5.1 mEq/L. Mean (standard deviation) serum K+ was 4.78 (0.51) mEq/L at baseline; weekly values were 4.48–4.70 mEq/L during treatment. Serum K+ of 3.5–5.5 mEq/L at the end of study treatment (primary endpoint) was achieved by 57 (90.5%) patients; 53 (84.1%) had serum K+ 4.0–5.1 mEq/L. One patient (1.6%) developed hypokalaemia, and two patients (3.2%) developed hypomagnesaemia. Spironolactone was increased to 50 mg/day in all patients; 43 (68%) patients required one or more patiromer dose titration. Adverse events (AEs) occurred in 36 (57.1%) patients, with a low rate of discontinuations [four (6.3%) patients]. The most common AE was mild to moderate abdominal discomfort [four (6.3%) patients]. In this open-label study, patiromer 16.8 g/day followed by individualized titration maintained serum K+ within the target range in the majority of patients with HF and CKD, all of whom were uptitrated to spironolactone 50 mg/day, patiromer was well tolerated, with a low incidence of hyperkalaemia, hypokalaemia, and hypomagnesaemia.Keywords
Funding Information
- Relypsa, Inc., a Vifor Pharma Group Company
- Relypsa, Inc., a Vifor Pharma Group Company
This publication has 29 references indexed in Scilit:
- Predictors of Hyperkalemia and Death in Patients With Cardiac and Renal DiseaseThe American Journal of Cardiology, 2012
- Eplerenone in Patients with Systolic Heart Failure and Mild SymptomsNew England Journal of Medicine, 2011
- Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trialEuropean Heart Journal, 2011
- The Frequency of Hyperkalemia and Its Significance in Chronic Kidney DiseaseArchives of internal medicine (1960), 2009
- Managing Hyperkalemia Caused by Inhibitors of the Renin–Angiotensin–Aldosterone SystemNew England Journal of Medicine, 2004
- Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial InfarctionNew England Journal of Medicine, 2003
- Limitation of Excessive Extracellular Matrix Turnover May Contribute to Survival Benefit of Spironolactone Therapy in Patients With Congestive Heart FailureCirculation, 2000
- The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart FailureNew England Journal of Medicine, 1999
- Effectiveness of Spironolactone Added to an Angiotensin-Converting Enzyme Inhibitor and a Loop Diuretic for Severe Chronic Congestive Heart Failure (The Randomized Aldactone Evaluation Study [RALES])**See Appendix for full list of RALES investigators.The American Journal of Cardiology, 1996
- Aldosterone in Congestive Heart Failure: Analysis of Determinants and Role in Sodium RetentionAmerican Journal of Nephrology, 1991